JP2000507214A - B細胞悪性疾患用ワクチン - Google Patents
B細胞悪性疾患用ワクチンInfo
- Publication number
- JP2000507214A JP2000507214A JP9529517A JP52951797A JP2000507214A JP 2000507214 A JP2000507214 A JP 2000507214A JP 9529517 A JP9529517 A JP 9529517A JP 52951797 A JP52951797 A JP 52951797A JP 2000507214 A JP2000507214 A JP 2000507214A
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- cells
- antigen
- malignant
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a)少なくとも1種のB細胞悪性腫瘍関連抗原と、 (b)単独でまたは少なくとも1種の他のサイトカインと組み合わせたI L−2と、 (c)少なくとも1種の脂質分子と を含むリポソーム製剤を含むワクチン。 2.前記抗原が悪性B細胞と関連があるかまたは悪性B細胞によって産生され た抗体の全部または一部を含むことを特徴とする、請求項1に記載のワクチン。 3.前記悪性B細胞がリンパ腫関連であることを特徴とする、請求項1に記載 のワクチン。 4.前記悪性B細胞が慢性リンパ性白血病関連であることを特徴とする、請求 項1に記載のワクチン。 5.前記悪性B細胞が多発性骨髄腫関連であることを特徴とする、請求項1に 記載のワクチン。 6.抗体または抗体フラグメントではない腫瘍関連抗原をさらに含む、請求項 2に記載のワクチン。 7.前記腫瘍関連抗原がMUC−1、EBV抗原またはバーキットリンパ腫関 連の抗原であることを特徴とする、請求項6に記載のワクチン。 8.非悪性B細胞によって産生されるか非悪性B細胞と関連のあるB細胞抗原 をさらに含む、請求項1に記載のワクチン。 9.前記B細胞抗原がクラス1のHLA抗原またはクラス2のHLA抗原であ ることを特徴とする、請求項8に記載のワクチン。 10.前記少なくとも1種の他のサイトカインがM−CSF、GM−CSF、 およびIFN−γから成る群から選択されることを特徴とする、請求項1に記載 のワクチン。 11.前記脂質分子がリン脂質、糖脂質、コレステロール、および前記各脂質 の誘導体から成る群から選択されることを特徴とする、請求項1に記載のワクチ ン。 12.キャリヤータンパクをさらに含む、請求項1に記載のワクチン。 13.前記キャリヤータンパクがアルブミンであることを特徴とする、請求項 12に記載のワクチン。 14.アジュバントをさらに含む、請求項1に記載のワクチン。 15.哺乳動物において、悪性B細胞に対する体液性免疫応答または細胞性免 疫応答を誘導する方法であって、前記哺乳動物に請求項1〜14のいずれか1項 に記載のワクチンを投与することを含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1178396P | 1996-02-16 | 1996-02-16 | |
US60/011,783 | 1996-02-16 | ||
PCT/US1997/002351 WO1997029769A1 (en) | 1996-02-16 | 1997-02-13 | Vaccine for b-cell malignancies |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000507214A true JP2000507214A (ja) | 2000-06-13 |
JP3948751B2 JP3948751B2 (ja) | 2007-07-25 |
Family
ID=21751949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52951797A Expired - Fee Related JP3948751B2 (ja) | 1996-02-16 | 1997-02-13 | B細胞悪性疾患用ワクチン |
Country Status (8)
Country | Link |
---|---|
US (2) | US6312718B1 (ja) |
EP (1) | EP0918539B1 (ja) |
JP (1) | JP3948751B2 (ja) |
AT (1) | ATE306937T1 (ja) |
AU (1) | AU2273497A (ja) |
CA (1) | CA2246708C (ja) |
DE (1) | DE69734392T2 (ja) |
WO (1) | WO1997029769A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011529870A (ja) * | 2008-08-01 | 2011-12-15 | コミッサリア ア レネルジ アトミック エ オー エネルジ アルターネイティブス | 異常bリンパ球増殖の治療におけるhla−gの可溶型の使用 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1523977A1 (en) * | 1997-10-01 | 2005-04-20 | Biomira Usa Inc. | Multilamellar coalescence vesicles (MLCV) containing biologically active compounds |
IN190388B (ja) | 1997-10-01 | 2003-07-26 | Biomira Usa Inc | |
CA2318557A1 (en) | 1998-01-16 | 1999-07-22 | Biomira Usa Inc. | Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes |
JP2002509102A (ja) * | 1998-01-16 | 2002-03-26 | バイオミラ・ユーエスエイ・インコーポレイテッド | リポマトリックス製剤 |
DE19954843C2 (de) * | 1999-11-09 | 2003-11-20 | Novosom Ag | Verfahren zur Verkapselung von Proteinen oder Peptiden in Liposomen, mit dem Verfahren hergestellte Liposomen und deren Verwendung |
US6911204B2 (en) | 2000-08-11 | 2005-06-28 | Favrille, Inc. | Method and composition for altering a B cell mediated pathology |
AU8330401A (en) * | 2000-08-11 | 2002-02-25 | Favrille Inc | Method and composition for altering a t cell mediated pathology |
JP2005525992A (ja) * | 2001-06-25 | 2005-09-02 | イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム | 生物学的物質を充填した小胞の調製法およびそれらの様々な使用 |
US8647627B2 (en) * | 2011-01-13 | 2014-02-11 | Oncbiomune, L.L.C. | Composition for a cancer vaccine |
US9725768B2 (en) | 2012-08-31 | 2017-08-08 | Biovest International, Inc. | Methods for producing high-fidelity autologous idiotype vaccines |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
AU4525589A (en) * | 1988-10-27 | 1990-05-14 | Regents Of The University Of Minnesota | Liposome immunoadjuvants containing il-2 |
US6099846A (en) * | 1992-10-14 | 2000-08-08 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of B cell lymphoma and tumor resistance using idiotype/cytokine conjugates |
US5861158A (en) * | 1993-11-17 | 1999-01-19 | The United States Of America As Represented By The Deptartment Of Health And Human Services | Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor |
-
1997
- 1997-02-13 JP JP52951797A patent/JP3948751B2/ja not_active Expired - Fee Related
- 1997-02-13 DE DE69734392T patent/DE69734392T2/de not_active Expired - Fee Related
- 1997-02-13 US US09/125,376 patent/US6312718B1/en not_active Expired - Lifetime
- 1997-02-13 AU AU22734/97A patent/AU2273497A/en not_active Abandoned
- 1997-02-13 WO PCT/US1997/002351 patent/WO1997029769A1/en active IP Right Grant
- 1997-02-13 EP EP97905966A patent/EP0918539B1/en not_active Expired - Lifetime
- 1997-02-13 AT AT97905966T patent/ATE306937T1/de not_active IP Right Cessation
- 1997-02-13 CA CA002246708A patent/CA2246708C/en not_active Expired - Fee Related
-
2001
- 2001-11-05 US US09/985,630 patent/US20030021838A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011529870A (ja) * | 2008-08-01 | 2011-12-15 | コミッサリア ア レネルジ アトミック エ オー エネルジ アルターネイティブス | 異常bリンパ球増殖の治療におけるhla−gの可溶型の使用 |
Also Published As
Publication number | Publication date |
---|---|
US6312718B1 (en) | 2001-11-06 |
AU2273497A (en) | 1997-09-02 |
DE69734392T2 (de) | 2006-07-13 |
CA2246708C (en) | 2005-06-14 |
EP0918539A4 (en) | 2001-04-11 |
EP0918539B1 (en) | 2005-10-19 |
WO1997029769A1 (en) | 1997-08-21 |
US20030021838A1 (en) | 2003-01-30 |
ATE306937T1 (de) | 2005-11-15 |
JP3948751B2 (ja) | 2007-07-25 |
EP0918539A1 (en) | 1999-06-02 |
DE69734392D1 (de) | 2006-03-02 |
CA2246708A1 (en) | 1997-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Phillips et al. | Enhanced antibody response to liposome-associated protein antigens: preferential stimulation of IgG2a/b production | |
JP4970035B2 (ja) | invivoにおける樹状細胞の標的化 | |
FR2774697A1 (fr) | Procede de sensibilisation de cellules presentatrices d'antigene et moyens pour la mise en oeuvre du procede | |
Reali et al. | IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines | |
Bei et al. | The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice | |
Caudill et al. | HSPPC-96: a personalised cancer vaccine | |
JPH11509558A (ja) | 免疫反応を惹起するための、多数エピトープ含有抗原の再構成法および組成物 | |
JP2000507214A (ja) | B細胞悪性疾患用ワクチン | |
WO2004024174A1 (ja) | 制御性t細胞の活性を制御する方法および組成物 | |
Wallis et al. | A liposome-based cancer vaccine for a rapid and high-titre anti-ErbB-2 antibody response | |
MX2007006717A (es) | Peptidos de alfa timocina como adyuvantes en vacunas contra el cancer. | |
WO1997029769A9 (en) | Vaccine for b-cell malignancies | |
Nijen Twilhaar et al. | Incorporation of toll-like receptor ligands and inflammasome stimuli in GM3 liposomes to induce dendritic cell maturation and T cell responses | |
EP0422164A1 (en) | LARGE SIZE MULTIVALENT IMMUNOGEN. | |
JP2002541811A (ja) | テロメラーゼ特異的癌ワクチン | |
SK6542002A3 (en) | The use of antibodies for the production of pharmaceutical composition useful as vaccines | |
JPH05504756A (ja) | 免疫刺激性を有する組成物と、そのヒトと獣医学用医薬への応用 | |
WO1998039027A2 (en) | Sialyl lewis antigens as targets for immunotherapy | |
EP0268640A1 (en) | Vaccine for stimulating or enhancing production of antibodies directed against gm2 | |
US20230381309A1 (en) | Methods of treating diffuse large b-cell lymphoma | |
JP2012506371A (ja) | 樹状細胞を標的とするための組成物 | |
US20050169929A1 (en) | Use of a vaccine for active immunization against cancer | |
JP2001508764A (ja) | 免疫原性tlp組成物 | |
JP2001501603A (ja) | ヌクレオソームに基づく抗腫瘍性組成物 | |
EP1118331A1 (en) | Method for enhancing the presentation of exogenous antigen by human antigen-presenting cells and opsonized micro particle complexes for applying this method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051115 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060215 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060403 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060515 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060718 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061115 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070215 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070320 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070417 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110427 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |